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Protease-activated receptors (PARs) are G-protein-coupled receptors which initiate inﬂammatory responses when activated by
speciﬁc serine proteases. This study was conducted to examine whether human conjunctival epithelial cells (HCECs) express
functionally active PAR1 and PAR2 using Chang conjunctival epithelial cells as in vitro model. We performed RT-PCR and im-
munoﬂuorescence analyses to determine the expression of PAR1 and PAR2, and monitored the production of IL-6 after activating
HCECs with PAR1 activating agents (thrombin or TFLLRN) or PAR2 activating agents (tryptase, trypsin, or SLIGKV). The results
show that HCECs constitutively express PAR1 and PAR2 mRNA and proteins, and produce signiﬁcant amounts of IL-6 when in-
cubated with speciﬁc PAR-activating enzymes or agonist peptides. Thrombin- and tryptase-induced HCEC activation was blocked
by PAR1 and PAR2 neutralizing antibodies, respectively, and by speciﬁc enzyme inhibitors. The constitutive expression of PAR1
and PAR2, and their activation by thrombin and tryptase, respectively, may have important implications in ocular inﬂammation.
Copyright © 2006 Timothy J. Nickel et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Allergic inﬂammation of the ocular conjunctiva is associated
with increased mast cell mediators in tear ﬂuid, and the re-
cruitment of activated eosinophils, mast cells, and lympho-
cytes [1]. Furthermore, ocular epithelial cells are active par-
ticipants in the regulation of allergic inﬂammation via ex-
pression of adhesion molecules and elaboration of proin-
ﬂammatory cytokines and chemokines [2]. Recent work has
highlighted the potential role of protease-activated receptors
(PARs)instimulatingcytokineproductionbyrespiratoryep-
ithelium [3]. In addition, Lang et al [4] have demonstrated
the presence of PAR1 and PAR2 in the corneal epithelium.
However, the expression and functions of PAR1 and PAR2 in
bulbar conjunctival epithelium have not been explored.
PARs are G-protein-coupled seven transmembrane re-
ceptors [5, 6] with a unique signaling mechanism. These
receptors have their own ligands embedded in their extra-
cellular N-terminal domains. Cleavage of the extracellular
domain by a speciﬁc serine protease frees the tethered lig-
and to activate the receptor [5]. Initial reports demonstrated
that this mechanism was operative in thrombin-induced
platelet activation [6]. To date, four subtypes of PARs have
been described [6–9], and among these, PAR1 and PAR2
are widely expressed in many cell types including endothe-
lial cells, platelets, bronchial epithelial cells, ﬁbroblasts, mast
cells, neurons, leukocytes, eosinophils, airway and vascular
smooth muscle cells, keratinocytes, and renal tubular cells
[3–14].
Because of the unique nature of their activation by pro-
teasesandthepresenceofactiveserineproteasesinbiological
ﬂuids, tissues, and allergens, PARs have been implicated in a
variety of inﬂammatory responses. These include expression
of P-selectin in endothelial cells [13], release of IL-6 by en-
dothelial cells [14] and production of proinﬂammatory cy-
tokine by bronchial epithelial cells [3], recruitment and acti-
vation of eosinophils [11, 15], and enhanced airway hyperre-
activity[15].AlthoughPAR1[6],PAR3[7],andPAR4[5]ar e
activatedbythrombin,PAR2isactivatedbymastcelltryptase
[16]a n dt r y p s i n[ 9]. Thus, both thrombin and tryptase act-
ing through PARs could perpetuate allergic inﬂammation in
the eye. This hypothesis is further supported by the ﬁnding
that tryptase levels are elevated in tear ﬂuid after allergen
challenge [1] and in vernal keratoconjunctivitis [17]. Mast2 Mediators of Inﬂammation
cellnumbersintheocularepitheliaandsubstantiapropriaare
increased in a variety of atopic ocular disorders [18]. Finally,
PAR2 is upregulated in the respiratory epithelia of patients
with asthma [19]. The results presented in the report show
that PAR1 and PAR2 mRNA and proteins are constitutively
expressed in HCECs and their stimulation by thrombin and
tryptase, respectively, results in the release of IL-6.
METHODS
Materials
Human conjunctival epithelial cells (HCECs, Wong Kil-
borne derivative of Chang epithelial cells) were obtained
from American Tissue Type Culture Collection. Epithelial
cell growth medium with N-2-hydroxyethylpiperazine-N -
2-ethane-sulfonic acid (HEPES), Hank’s balanced salt so-
lution (HBSS), trypsin-EDTA, and trypsin neutralizing so-
lution (TNS) were purchased from Cambrex (San Diego,
Calif). Eagles’ minimum essential medium (MEM) and fe-
tal bovine serum (low endotoxin) were purchased from Hy-
clone Laboratories (Logan, Utah). Hirudin, heparin, nonen-
zymic cell dissolution reagent, penicillin, and streptomycin
weresuppliedbySigmaChemicalCo(StLouis,Mo).Throm-
bin, trypsin, tryptase, pertussis toxin, and trypsin inhibitor
were purchased from Calbiochem (La Jolla, Calif). Hu-
m a nI L - 6E L I S Ak i t sw e r ep u r c h a s e df r o mR&Ds y s -
tems (Minneapolis, Minn). PAR1 and PAR2 activating pep-
tides (TFLLRN and SLIGKV) and inactive peptides which
lacked consensus sequences but retained the same amino
acid compositions (LFTNRL and ILSVKG) were synthesized
by Syn Pep Corp (Dublin, Calif) and HPLC-puriﬁed at the
Biotechnology Facility of Kansas University Medical Cen-
ter (Kansas City, Kan). Mouse antihuman PAR1 (ATAP2)
and mouse antihuman PAR2 (SAM11) were purchased from
Santa Cruz (South San Francisco, Calif). Mouse antihu-
man PAR1 (WEDE 15) was purchased from Fisher Scien-
tiﬁc. Mouse isotype IgG2a and CYTM3-conjugated aﬃnipure
goat antimouse IgG were obtained from Chemicon (Temec-
ula, Calif) and Jackson ImmunoResearch Laboratories (West
Grove, Pa), respectively. The chamber slides used for im-
munoﬂuorescecestudieswereproductsofLabtec,Nalgenunc
International (Naperville, Ill). Primers and RT-PCR reagents
for PAR1 and PAR2 were purchased from Invitrogen (Carls-
bad, Calif). Antifade was supplied by Molecular Probe (Eu-
gene, Ore).
Cultureofhumanconjunctivalepithelialcells
HCECs were grown in Eagle’s MEM with glutamine sup-
plemented with 15mM HEPES, 100 units/mL penicillin,
100μg/mL streptomycin, and with or without 10% fetal
bovine serum (complete medium). At conﬂuence, the cells
were detached from the culture ﬂasks using trypsin-EDTA
or cell dissolution solution (depending on the experimen-
tal conditions), washed twice, and resuspended in serum-
free medium. All experiments were performed using HCECs
maintained between three and nine passages after obtaining
the cells from ATCC.
AssayofIL-6production
HCECs(2×104)incompletemediumwereseededontoeach
of the wells of a 96-well microtiter plate and allowed to ad-
here for 24 hours. Following adherence, the culture medium
was removed, serum-free medium (complete medium with-
out serum) was added, and the monolayers were incubated
with selected concentrations of the agonists in a ﬁnal vol-
umeof0.2mLserum-freemedium.Allincubationswerecar-
ried out at 37◦C in 5% humidiﬁed CO2 for 24 hours. Af-
ter incubation, culture supernatants were collected and IL-6
levels quantiﬁed by ELISA according to the manufacturer’s
protocol.
Semiquantitativereversetranscription-polymerase
chainreaction(RT-PCR)fordetection
ofmRNAforPAR1andPAR2
Total RNA was isolated from HCECs using TRIzol reagent
and treated with RNAse–free DNAse I. For the reverse tran-
scriptionreaction,superscriptIIRNaseH− reversetranscrip-
tasesystemwasemployed.PCRampliﬁcationwasperformed
with Taq polymerase for 32 cycles at 94◦C for 30s, 55◦Cf o r
30s, and 72◦C for 30s, and, ﬁnally 72◦Cf o r5m i n .A f t e ra m -
pliﬁcation, the products were subjected to electrophoresis on
a 2% agarose gel containing ethidium bromide and analyzed
under UV light against DNA molecular markers. The follow-
ing primers were used:
PAR1: 5 -TGTGAACTGATCATGTTTATG-3  and
5 -TTCGTAAGATAAGAGATATGT-3 
PAR2: 5 -TGGATGAGTTTTCTGCATCTGTCC-3  and
5 -CGTGATGTTCAGGGCAGGAATG-3 .
Ampliﬁcation of cDNA yielded 708 and 490 base-pair prod-
ucts for PAR1 and PAR2, respectively, as predicted.
DeterminationofPAR1andPAR2proteinexpression
byimmunoﬂourescence
HCECs (2 × 104) were plated in the wells of an 8-chamber
slide and incubated under the atmosphere of 5% CO2.F o l -
lowing adherence, cells were washed twice with phosphate
buﬀersaline(PBS),andﬁxedwith4%paraformaldehyde.Af-
ter ﬁxing, cells were treated with blocking buﬀer (1% bovine
serum albumin and 5% normal goat serum in PBS, pH 7.5,
with 0.3% Triton X−100) for one hour. Primary mouse an-
tibodies against PAR1 and PAR2 diluted 1 : 200 with the an-
tibody diluent (1% bovine serum albumin, 0.05% sodium
azide, and 5% normal goat serum in PBS, pH 7.5, with 0.3%
Triton X−100) were then added. Following overnight incu-
bation at 4◦C, monolayers were washed, and treated with a
secondary goat antimouse antibody (CY3) (diluted 1 : 200
with antibody diluent) for 1 hour. The monolayers were then
washed with PBS, treated with antifade, and viewed with a
ﬂuorescent microscope.
Statisticalanalysis
Statistics were computed using SPSS 10.0 (SPSS, Chicago,
Ill). Two-tailed P-values <.05 were taken to signify signiﬁ-
cance. For each experiment, treatments were ﬁrst comparedTimothy J. Nickel et al 3
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Figure 1: (a) RT-PCR analyses of the constitutive expression of PAR1 and PAR2 mRNA. Total RNA was extracted, reverse transcribed, and
ampliﬁed using PAR1- and PAR2-speciﬁc primers as described under “Methods” section. The ampliﬁed products were electrophoresed on
a 2% agarose gel. The result presented is representative of three independent experiments. (b) Immunoﬂourescence analyses of the expression
of PAR1 and PAR2 proteins. The cultured HCECs were ﬁxed with paraformaldehyde and were incubated with speciﬁc primary antibodies
or isotype IgG. After extensive washing, the cells were incubated with rhodamine-conjugated secondary antibodies and viewed under a
ﬂuorescence microscope for imaging.
to the medium-only control using Dunnett’s test. Then, to
testfordiﬀerencesamongtreatments,iftheone-wayANOVA
was signiﬁcant, post hoc comparisons were made using
the Student-Newman-Keuls test. Dose-response curves were
modeled using one-df linear and quadratic orthogonal poly-
nomial contrasts, with strength of association indexed by η2.
Ap e r f e c tc o r r e l a t i o ni se q u a lt o1 .
RESULTS
PAR1andPAR2expressioninhumanconjunctival
epithelialcells
RT-PCR was used to examine PAR1 and PAR2 mRNA ex-
pression in HCECs. As shown in Figure 1(a), HCECs con-
stitutively express PAR1 and PAR2 mRNA. Since mRNA ex-
pression does not always correlate with protein expression,
immunoﬂuorescence analyses were carried out to identify
the presence of PAR1 and PAR2 proteins in HCECs. As
shown in Figure 1(b), immunoﬂuorescent staining utilizing
speciﬁc antibodies conﬁrmed that HCECs constitutively ex-
press PAR1 and PAR2 proteins.
FunctionalactivityofPAR1andPAR2
Previous reports document that thrombin induces IL-6 pro-
duction by human umbilical vein endothelial cells [14]a n d
bronchial epithelial cells [3]. In addition, trypsin induces
cytokine production in corneal [4] and bronchial epithelial
cells [3]. Therefore, to determine the functional responsive-
ness of PAR1 and PAR2, the cells were incubated with diﬀer-
ent concentrations of thrombin, tryptase, or trypsin, and the
levels of secreted IL-6 were quantiﬁed by ELISA. As shown in
Figure 2(a),incubationwiththrombin(14–220nM)resulted
in a dose-dependent increase in IL-6 production. Incuba-
tion of HCECs with tryptase (55–220nM) or trypsin (55–
220nM) also stimulated IL-6 production in a concentration-
dependent manner (Figures 2(b) and 2(c)).
Thrombin cleavage of PAR1 exposes a new N-terminus
with the sequence SFLLRN which acts as a tethered lig-
and. Similarly, PAR2 cleaving enzymes expose the unique se-
quence SLIGKV on the extracellular domain of the recep-
tor. Therefore, synthetic hexapeptides bearing these amino
acid sequences were utilized to verify the speciﬁcity of each
of these PARs. These synthetic PAR-activating peptides can
activate speciﬁc PARs without inducing proteolytic cleav-
age [10]. In the case of PAR1 agonist, we used TFLLRN in-
stead of SFLLRN since substitution of threonine for serine
prevents cross-desensitization of PAR2 and makes the ag-
onist more PAR1-speciﬁc [20]. Incubation of HCECs with
TFLLRN (Figure 3(a)) and SLIGKV (Figure 3(b))r e s u l t e di n
an increase in IL-6 production. The control peptides, which
lacked consensus sequences (LFTNRL and ILSKVG) but had
the same amino acid composition as active peptides, did not
activate HCECs to secrete IL-6.
EffectsofinhibitingproteaseactivityandG-protein
couplingonPAR-mediatedIL-6release
The requirement for catalytic activity for thrombin and
trypsin for stimulation of PAR1 and PAR2, respectively,
was conﬁrmed by incubating thrombin with a selective in-
hibitor, hirudin, and trypsin with a selective inhibitor, soy-
bean trypsin inhibitor. As depicted in Figure 4, the ability of
thrombin and trypsin to induce IL-6 production by HCECs
was completely abrogated when enzymes were treated with
their speciﬁc inhibitors. In control studies, hirudin did not
inhibit trypsin activity nor did soybean trypsin inhibitor in-
hibit thrombin activity on HCECs (data not shown).4 Mediators of Inﬂammation
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Figure 2: Thrombin-, tryptase-, and trypsin-stimulated IL-6 produc-
tion by HCECs. HCEC monolayers were incubated with the indi-
cated concentrations of thrombin (a), tryptase (b), or trypsin (c).
After a 24-hour culture, IL-6 levels in the culture media were as-
sayed by ELISA. Each value presented is the mean + / − SD of qua-
druplicate determinations. The results presented are representatives
of four independent experiments.
∗indicates P<.05 when compared to medium control.
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Figure 3: PAR1 and PAR2 agonist peptides stimulate IL-6 produc-
tion in HCECs. HCEC monolayers were incubated with PAR1 ago-
nistpeptide(TFLLRN)orscrambledpeptide(LFTNRL)(a),orwith
the PAR2 agonist peptide (SLIGKV) or inactive peptide (ILSVKG)
(b). After 24 hours, IL-6 levels in the culture media were assayed by
ELISA. Each value presented is the mean + / − SD of quadruplicate
determinations. The results presented are representatives of six in-
dependent experiments.
∗indicates P<.05 when compared to medium control.
It is well-recognized that the PAR-signaling pathway re-
quires G-protein coupling [5, 21]. Therefore, the eﬀect of
the G-protein-coupled receptor inhibitor, pertussis toxin, on
thrombin- and tryptase-induced IL-6 production was tested.
As shown in Figure 5, preincubation of HCECs with pertus-
sis toxin for 30 minutes prior to the addition of thrombin or
trypsin completely inhibited IL-6 release.
InhibitionofPAR1andPAR2activation
byreceptorspeciﬁcantibody
To further determine the speciﬁcity of PAR-mediated acti-
vation, HCECs were incubated with speciﬁc antibodies that
block the enzymatic cleavage of PARs. The antibodies WEDE
15 and ATAP 2 bind PAR1 near its cleavage site. This combi-
nation has previously been shown to result in complete inhi-
bition of thrombin-induced activation of human umbilicalTimothy J. Nickel et al 5
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Figure 4: Requirement of the enzymic activity of thrombin and
trypsin for HCEC activation. HCEC monolayers were incubated
with thrombin (220 nM), thrombin+hirudin (4U/mL), trypsin, or
trypsin + soybean trypsin inhibitor (STI) (100U/mL) for 24 hours
at 37◦C. Unactivated cells produced 107 ± 12pg/mL of IL-6. The
presence of hirudin or STI to unstimulated cells did not alter IL-6
production. The results presented are representatives of two inde-
pendent experiments.
∗indicates P<.05 when compared to medium control.
endothelial cells [24]. The antibody SAM11 binds to PAR2
near its cleavage region. As shown in Figure 6(a), incuba-
tion of HCECs with thrombin in the presence of WEDE 15
plusATAP2resultedinthecompleteinhibitionofthrombin-
stimulated IL-6 production, whereas PAR2 neutralizing anti-
bodies showed no eﬀect (Figure 6(a)). Similarly, incubation
of HCECs with PAR2 blocking antibody SAM11 resulted in
complete inhibition of trypsin- and tryptase- induced IL-6
production (Figures 6(b) and 6(c)), while antibodies against
PAR1 were without eﬀect.
DISCUSSION
Theresultsofthepresentstudydemonstratefortheﬁrsttime
that HCECs constitutively express PAR1 and PAR2 mRNA
and protein (Figures 1(a) and 1(b)). Furthermore, PAR1 and
PAR2 speciﬁc proteases induce a signiﬁcant increase in IL-
6p r o d u c t i o n( Figure 2). This response can be blocked with
theadditionofspeciﬁcantibodiesthatbindnearthecleavage
site of PAR1 or PAR2 or with selective inhibitors of the pro-
tease. Finally, the speciﬁcity of the PAR1 and PAR2 mediated
response is conﬁrmed by the ability of the PAR1 activating
peptideTFLLRNandthePAR2activatingpeptideSLIGKVto
induce IL-6 production by HCECs. This conﬁrms that both
PARs are expressed and are functional.
It has been shown previously that both trypsin and
tryptase at high concentrations may cleave PAR1 in vitro, in
addition to PAR2 [16]. In the present study, incubation of
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Figure 5: Inhibition of thrombin- and trypsin-induced IL-6 produc-
tion by pertussis toxin. The HCEC monolayers were incubated with
pertussis toxin (PT) (1μg/mL) for 30 minutes and challenged with
thrombin (220nM) or trypsin (220nM). Unactivated cells pro-
duced 107±12pg/mL of IL-6. The results presented are representa-
tive of two independent experiments.
∗indicates P<.05 when compared to medium control.
HCECs with the antibodies to the PAR1 cleavage region did
not inhibit the eﬀects of trypsin and tryptase, whereas PAR2
blocking antibodies completely abrogated the eﬀects of these
enzymes. This indicates that the eﬀects of thrombin, trypsin,
and tryptase are indeed mediated through speciﬁc activation
of PAR1 and PAR2, and there was no crosstalk between the
PARs at the concentrations of the proteases used here. These
results are consistent with a previous report that demon-
strated the cleavage of peptides derived from PAR1 with high
levels of trypsin and tryptase in transfected COS-1 cells, but
no cleavage of endogenous PAR1 in platelets or CHRF-288
cells [16]. Alternatively, since thrombin has been reported to
cleave PAR3 and PAR4 [5, 21], cell activation could be at-
tributed to these receptors, if present. However, the complete
inhibition of activation attained with the PAR1 antibodies
suggests that the thrombin eﬀect in this cell line is due to
PAR1.
The activation of PAR1 and PAR2 shares common
signal transduction pathways including G-protein-coupled
receptor activation [5, 21]. The complete inhibition of
thrombin- and tryptase-induced IL-6 release by pertussis
toxin (Figure 5) conﬁrms the involvement of G-proteins in
protease-mediated HCEC activation. One could speculate
that PAR2, present in ocular conjunctiva and known to
be upregulated in allergic airways disease, is activated by
tryptase released as a result of mast cell degranulation. Mast
cell tryptase is increased in tear ﬂuid in a variety of aller-
gic ocular diseases [17, 22, 23]. The protease activity of tear
ﬂuid tryptase, however, is not known, but should be studied
to ascertain if the above mechanisms are plausible. Another6 Mediators of Inﬂammation
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Figure 6: PAR1 and PAR2 neutralizing antibodies selectively inhibit the eﬀects of thrombin, tryptase, and trypsin. HCEC monolayers were
incubated for 15 minutes with a cocktail of PAR1 blocking antibodies, ATAP-2 (25μg/mL), and WEDE 15 (25μg/mL), or the PAR2 blocking
antibody, SAM11 (25μg/mL), prior to stimulation for 24 hours with thrombin (50 nM) (a), tryptase (50nM) (b), and trypsin (50nM) (c).
IL-6 levels in the culture media were then assayed by ELISA. Each value presented is the mean +/ −SD of quadruplicate determinations.
∗indicates P<.05 when compared to medium control.
recently described activator of PAR2 in the airway is human
airwaytrypsin-likeprotease(HAT),whichhasbeenshownto
activate PAR2 in human bronchial epithelial cells [25] and in
psoriatic skin [26]. The presence of an additional PAR2 ago-
nist in tear ﬂuid is unknown. The presence of an endogenous
PAR1 activator in the ocular conjunctiva has not been iden-
tiﬁed. Althoughrecentworkhas pointed to increased throm-
bin activity in human airway BAL ﬂuid in an allergen chal-
lengemodel[27],thrombinactivityintearﬂuidhasnotbeen
reported. Future studies are needed to characterize protease
activityintearﬂuidanddeterminetherelevantphysiologyof
PAR receptors in the conjunctiva. In the current study with
the HCECs, the proteases including thrombin, trypsin, and
tryptase are equally active in stimulating IL-6 release when
compared on a molar basis.
OfparticularrelevancetotheroleofPARsinconjunctival
inﬂammationistheﬁndingthatsomeallergenswithprotease
activity have the potential to directly activate PARs. King et
al [28] showed that the mite cysteine and serine proteolytic
allergens, Der p-1 and Der p-9, induced cytokine production
from human bronchial epithelial cells. This eﬀect could be
blocked with protease inhibitors. Further work has demon-
stratedthatDerp-1[29],Derp-3[30],andDerp-9[30]acti-
vationofrespiratoryepitheliumismediated,atleastpartially,
by PAR2. More recently, cockroach extract has been shown
to activate PAR2 in human airway epithelial cells [31, 32],
and the cysteine proteases, papain, and Der f-1 can activate
eosinophils [33, 34]. If proteolytic allergen activation of con-
junctival PARs also occurs, these receptors may play a role in
inﬂammation independent of allergic sensitization and mastTimothy J. Nickel et al 7
cell degranulation. This is particularly relevant in the eye
which, along with the respiratory epithelium, represents a
major site of environmental allergen exposure. Whether this
phenomenon may cause symptoms irrespective of IgE sen-
sitization, or whether this may simply facilitate or augment
initial sensitization by inducing an early inﬂammatory inﬁl-
trate, is currently unknown.
Numerous reports also show that PARs may play im-
portant roles in allergic airway disease [35–39]. In murine
models,PARknockoutmicehaveshownmarkedattenuation
in eosinophil recruitment and airway hyperreactivity in re-
sponse to allergen challenge [40] .T h ep r e s e n c eo fP A R 1a n d
PAR2 in the conjunctival and corneal epithelium provides
the opportunity to uncover their physiologic relevance and
develop strategies using peptide agonists and/or antagonists
to manipulate disease processes at the ocular surface.
ABBREVIATIONS
PAR: Protease-activated receptor.
HCECs: Human conjunctival epithelial cells.
PAR-AP: Protease-activated receptor activating peptide.
TFLLRN: PAR1 activating peptide, re-phe-leu-leu-arg-asn.
SLIGKV: PAR2 activating peptide, ser-leu-iso-gly-lys-val.
SBTI: Soybean trypsin inhibitor.
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